ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.505,70
0,47%
S&P 500
6.037,88
0,72%
Dow Jones
44.556,04
0,30%
Euro vs US Dollar
1,03817
0,09%
Bitcoin
98.360,70
0,51%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Aurinia Pharmaceuticals Inc (AUPH) Börsenkurse

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc (AUPH)

NASDAQ
8,01
0,20
(2,56%)
Geschlossen 05 Februar 10:00PM
Verzögert um 15 Minuten
7,85
-0,16
(-2,00%)
Nach Börsenschluss: 1:20AM
Verzögert um 15 Minuten

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
7,85
Gebot
7,85
Fragen
8,01
Volumen
843.917
7,78 Tagesbereich 8,035
4,71 52-Wochen-Bereich 10,67
Marktkapitalisierung
1,122B
Handelsende
7,81
Handelsbeginn
7,81
Letzte Trade
300
@
7.85
(formt)
Letzter Handelszeitpunkt
Finanzvolumen
US$ 6.663.472
VWAP
7,8959
Durchschnittliches Volumen (3 Mio.)
1.380.873
Ausgegebene Aktien
142.990.974
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-14,68
Gewinn pro Aktie (EPS)
-0,55
Erlöse
175,51M
Nettogewinn
-78,02M

Über Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FS... Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
www.auriniapharma.com
Hauptsitz
Victoria, British Columbia, Can
Gegründet
-
Aurinia Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AUPH. The last closing price for Aurinia Pharmaceuticals was US$7,81. Over the last year, Aurinia Pharmaceuticals shares have traded in a share price range of US$ 4,71 to US$ 10,67.

Aurinia Pharmaceuticals currently has 142.990.974 shares in issue. The market capitalisation of Aurinia Pharmaceuticals is US$1,12 billion. Aurinia Pharmaceuticals has a price to earnings ratio (PE ratio) of -14.68.

AUPH Neueste Nachrichten

Weitere Nachrichten

Form 4 - Statement of changes in beneficial ownership of securities

25 November 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

25 November 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

25 November 2024
Edgar (US Regulatory)

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen Aurinia Pharmaceuticals Inc...

18 November 2024
Business Wire

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR...

15 November 2024
Business Wire

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 November 2024
Edgar (US Regulatory)

Aurinia to Participate in Jefferies London Healthcare Conference

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the Jefferies Healthcare Conference in London, November 19-21...

14 November 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

13 November 2024
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

13 November 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 November 2024
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.43-5.193236714988.288.547.6659826308.01641729CS
4-0.63-7.429245283028.488.57127.5213430457.94743668CS
12-0.6-7.100591715988.4510.677.5213808738.68816735CS
262.5447.83427495295.3110.675.19513099017.7106627CS
520.283.698811096437.5710.674.7115005026.56359147CS
156-8.85-52.99401197616.720.47524.0721980278.75004367CS
260-10.98-58.311205523118.8333.97154.07247784112.55406846CS

AUPH - Frequently Asked Questions (FAQ)

What is the current Aurinia Pharmaceuticals share price?
The current share price of Aurinia Pharmaceuticals is US$ 7,85
How many Aurinia Pharmaceuticals shares are in issue?
Aurinia Pharmaceuticals has 142.990.974 shares in issue
What is the market cap of Aurinia Pharmaceuticals?
The market capitalisation of Aurinia Pharmaceuticals is USD 1,12B
What is the 1 year trading range for Aurinia Pharmaceuticals share price?
Aurinia Pharmaceuticals has traded in the range of US$ 4,71 to US$ 10,67 during the past year
What is the PE ratio of Aurinia Pharmaceuticals?
The price to earnings ratio of Aurinia Pharmaceuticals is -14,68
What is the cash to sales ratio of Aurinia Pharmaceuticals?
The cash to sales ratio of Aurinia Pharmaceuticals is 6,53
What is the reporting currency for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Aurinia Pharmaceuticals?
The latest annual turnover of Aurinia Pharmaceuticals is USD 175,51M
What is the latest annual profit for Aurinia Pharmaceuticals?
The latest annual profit of Aurinia Pharmaceuticals is USD -78,02M
What is the registered address of Aurinia Pharmaceuticals?
The registered address for Aurinia Pharmaceuticals is 1203-4464 MARKHAM STREET, VICTORIA, BRITISH COLUMBIA, V8Z 7X8
What is the Aurinia Pharmaceuticals website address?
The website address for Aurinia Pharmaceuticals is www.auriniapharma.com
Which industry sector does Aurinia Pharmaceuticals operate in?
Aurinia Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
CAPTCaptiVision Inc
US$ 1,024
(133,26%)
245,98M
QNTMQuantum Biopharma Ltd
US$ 6,70
(110,69%)
74,67M
LTRYLottery com Inc
US$ 0,58
(85,90%)
129,21M
CPIXCumberland Pharmaceutical Inc
US$ 3,7801
(77,47%)
18,29M
INKTMiNK Therapeutics Inc
US$ 12,08
(53,69%)
349,84k
OMGAOmega Therapeutics Inc
US$ 0,1473
(-69,25%)
11,7M
VIRXViracta Therapeutics Inc
US$ 0,0352
(-54,76%)
6,33M
CYNCYNGN Inc
US$ 0,0708
(-39,44%)
137,27M
UPCUniverse Pharmaceuticals Inc
US$ 0,2663
(-36,20%)
1,9M
CSAICloudastructure Inc
US$ 12,98
(-31,68%)
57,03k
NVDANVIDIA Corporation
US$ 118,65
(1,71%)
247,88M
CAPTCaptiVision Inc
US$ 1,024
(133,26%)
245,98M
PLTRPalantir Technologies Inc
US$ 103,83
(23,99%)
212,8M
RGTIRigetti Computing Inc
US$ 13,71
(1,78%)
150,62M
CYNCYNGN Inc
US$ 0,0708
(-39,44%)
134,49M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
AUPH
Aurinia Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten